Graves' Ophthalmopathy: A New Drug, an Old Standby, and Who Actually Gets It
A woman's eyes are visibly worsening from Graves' ophthalmopathy, and the newest, most effective drug for it also happens to carry real risk for a patient with her exact other diagnosis. The disagreement is whether the drug's power outweighs what it could do to her blood sugar.
Marisol T., a 51-year-old bank branch manager, had her Graves' disease brought under control with methimazole eight months ago, but her eyes have gotten steadily worse since — visible proptosis, new double vision when she looks to the side, and a swollen, uncomfortable quality to her eyelids that has started showing up in the photos her coworkers take at branch events. Her ophthalmologist has staged her thyroid eye disease as moderate-to-severe and active, not burned out, based on serial exams over the past two months. She also has type 2 diabetes, diagnosed six years ago, with an A1c that has run around 7.8% on metformin and glipizide — not tightly controlled, but not acutely dangerous either.
Teprotumumab, an IGF-1 receptor inhibitor approved specifically for thyroid eye disease, produced dramatic results in its pivotal trial — a majority of treated patients had a clinically meaningful reduction in proptosis, a response rate well beyond what corticosteroids or rituximab have shown in their own trials. But that same trial, and the drug's labeling, flag hyperglycemia as a genuine, mechanism-linked adverse effect, not an incidental one: IGF-1 receptor signaling overlaps with insulin signaling closely enough that blocking it can measurably worsen glycemic control, particularly in a patient who already has diabetes rather than one starting from normal glucose tolerance. Traditional high-dose intravenous corticosteroids remain a real alternative with their own long track record, weaker average efficacy against proptosis specifically, and their own, different metabolic cost — corticosteroids reliably raise blood sugar too, just through a different, more familiar mechanism clinicians are more practiced at managing around.
Choosing between the drug that works best and the drug her diabetes tolerates better
I'd recommend teprotumumab. Her disease is active and progressing, and the OPTIC trial showed a response rate on proptosis meaningfully beyond what steroids or rituximab have demonstrated in their own trials — for active, worsening moderate-to-severe disease like hers, it's the most effective option we have, and delaying it while her double vision worsens has its own real cost to her.
I'd want real caution here. Teprotumumab's hyperglycemia risk isn't incidental — it comes directly from IGF-1 receptor blockade overlapping with insulin signaling, and she's not starting from normal glucose tolerance, she's starting from an A1c already at 7.8% on two agents.
You're weighing the drug's efficacy against not treating at all, but the real comparison is against IV corticosteroids, which also reliably raise blood sugar — just through a mechanism we're far more practiced at anticipating and managing around than we are with an IGF-1R inhibitor in a diabetic patient.
I don't think her diabetes should rule teprotumumab out, but it should change how it's given. Proceed with teprotumumab given how active and functionally impactful her disease is, but pair it with proactive glycemic monitoring and a specific plan to intensify her diabetes regimen at the first sign of drift, rather than waiting for her A1c to climb before reacting. Her diabetes is a real reason to manage this more carefully, not a reason to default her to a less effective drug that carries its own glycemic cost anyway.
Agreed: proceed with teprotumumab, with glucose monitoring intensified and her diabetes regimen pre-planned for early escalation rather than reactive adjustment.
Not agreed: how aggressively to intensify her diabetes regimen before starting, versus reactively once glucose trends actually appear. The endocrinologist would add a third diabetes agent preemptively, before the first infusion; the ophthalmologist preferred starting her current regimen unchanged and adjusting only if glucose monitoring shows real drift, wary of adding medication burden for a risk that hasn't yet materialized.